

Statistical analysis plan APIDP

CHU de Caen Sponsor – Confidential Document
Protocol: Api-DP
EudraCT No.: 2019-001307-20 / CHU No.: 19-060

NCT04006093

Statistical analysis plan APIDP

The sample size was not computed based on a statistical hypothesis. We empirically considered including 12 ESRD patients on peritoneal dialysis, and 12 healthy volunteers controls matched based on sex, age (\pm 5 years) and weight (\pm 20%).

Baseline characteristics of the including subjects were described using mean (\pm standard deviation) for quantitative variables and number (percentage) for qualitative variables.

Pharmacokinetics parameters were described using geometric means (and standard error) by group. For each PK parameter, we computed a geometric mean ratio ESRD/Normal renal subjects (controls) and its 95% confidence interval. The PK parameter values were compared between groups by the use of paired *t*-test with lognormal distribution to request an analysis in terms of geometrics mean.

The correlation between Anti-factor Xa activity and apixaban plasma drug concentration were assessed at different times by the use of Spearman coefficient.

A two-tailed *p*-value below 0.05 was considered to denote statistical significance. We used SAS software v9.4 (SAS Institute and C carry) and R (version 3.6.2).